179 related articles for article (PubMed ID: 21063768)
1. Protective effects of YC-1 against glutamate induced PC12 cell apoptosis.
Yang X; Wang Y; Luo J; Liu S; Yang Z
Cell Mol Neurobiol; 2011 Mar; 31(2):303-11. PubMed ID: 21063768
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft.
Berkan O; Bagcivan I; Kaya T; Yildirim K; Yildirim S; Doğan K
Can J Physiol Pharmacol; 2007 May; 85(5):521-6. PubMed ID: 17632587
[TBL] [Abstract][Full Text] [Related]
3. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation.
Feelisch M; Kotsonis P; Siebe J; Clement B; Schmidt HH
Mol Pharmacol; 1999 Aug; 56(2):243-53. PubMed ID: 10419542
[TBL] [Abstract][Full Text] [Related]
4. Prolonged exposure to YC-1 induces apoptosis in adrenomedullary endothelial and chromaffin cells through a cGMP-independent mechanism.
Ferrero R; Torres M
Neuropharmacology; 2001 Dec; 41(7):895-906. PubMed ID: 11684154
[TBL] [Abstract][Full Text] [Related]
5. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats.
Hsieh GC; O'Neill AB; Moreland RB; Sullivan JP; Brioni JD
Eur J Pharmacol; 2003 Jan; 458(1-2):183-9. PubMed ID: 12498924
[TBL] [Abstract][Full Text] [Related]
6. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
Fraser M; Chan SL; Chan SS; Fiscus RR; Tsang BK
Oncogene; 2006 Apr; 25(15):2203-12. PubMed ID: 16288207
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of the nitric oxide receptor, soluble guanylyl cyclase, in cerebellar cells.
Bellamy TC; Garthwaite J
Br J Pharmacol; 2002 May; 136(1):95-103. PubMed ID: 11976273
[TBL] [Abstract][Full Text] [Related]
8. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
[TBL] [Abstract][Full Text] [Related]
9. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.
Galle J; Zabel U; Hübner U; Hatzelmann A; Wagner B; Wanner C; Schmidt HH
Br J Pharmacol; 1999 May; 127(1):195-203. PubMed ID: 10369473
[TBL] [Abstract][Full Text] [Related]
10. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
11. An evolutionarily conserved mechanism for sensitization of soluble guanylyl cyclase reveals extensive nitric oxide-mediated upregulation of cyclic GMP in insect brain.
Ott SR; Delago A; Elphick MR
Eur J Neurosci; 2004 Sep; 20(5):1231-44. PubMed ID: 15341595
[TBL] [Abstract][Full Text] [Related]
12. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one inhibits neurite outgrowth and causes neurite retraction in PC12 cells independently of soluble guanylyl cyclase.
Lee HG; Kim SY; Kim du S; Seo SR; Lee SI; Shin DM; De Smet P; Seo JT
J Neurosci Res; 2009 Jan; 87(1):269-77. PubMed ID: 18711750
[TBL] [Abstract][Full Text] [Related]
13. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel.
Dismuke WM; Sharif NA; Ellis DZ
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3353-9. PubMed ID: 19234350
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
[TBL] [Abstract][Full Text] [Related]
15. The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cells.
Ramos-Espiritu LS; Hess KC; Buck J; Levin LR
J Pharmacol Exp Ther; 2011 Sep; 338(3):925-31. PubMed ID: 21665942
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.
Chien WL; Liang KC; Teng CM; Kuo SC; Lee FY; Fu WM
Mol Pharmacol; 2003 Jun; 63(6):1322-8. PubMed ID: 12761342
[TBL] [Abstract][Full Text] [Related]
17. Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat.
Wegener JW; Gath I; Förstermann U; Nawrath H
Br J Pharmacol; 1997 Dec; 122(7):1523-9. PubMed ID: 9421305
[TBL] [Abstract][Full Text] [Related]
18. Does nitric oxide modulate transmitter release at the mammalian neuromuscular junction?
Nickels TJ; Reed GW; Drummond JT; Blevins DE; Lutz MC; Wilson DF
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):318-26. PubMed ID: 17324144
[TBL] [Abstract][Full Text] [Related]
19. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
[TBL] [Abstract][Full Text] [Related]
20. Role of the soluble guanylyl cyclase alpha1/alpha2 subunits in the relaxant effect of CO and CORM-2 in murine gastric fundus.
De Backer O; Elinck E; Sips P; Buys E; Brouckaert P; Lefebvre RA
Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):493-502. PubMed ID: 18563392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]